Clinical Trial Update: Quality of Life in Adalimumab Treated Psoriasis Patients Failing Other Biologic Disease Modifying Anti-rheumatic Drugs

View source ↗

Summary

This update reports results from a trial evaluating quality of life in psoriasis patients treated with adalimumab after failure of other biologic DMARDs.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: Abbott | Conditions: Psoriasis Chronic | Status: COMPLETED | Results posted: 2012-05-30